Cargando…
Cost-effectiveness analysis for clinicians
In a climate of economic uncertainty, cost effectiveness analysis is a potentially important tool for making choices about health care interventions. Methods for such analyses are well established, but the results need to be interpreted carefully and are subject to bias. Making decisions based on re...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395827/ https://www.ncbi.nlm.nih.gov/pubmed/22296610 http://dx.doi.org/10.1186/1741-7015-10-10 |
_version_ | 1782238040492605440 |
---|---|
author | Hill, Suzanne R |
author_facet | Hill, Suzanne R |
author_sort | Hill, Suzanne R |
collection | PubMed |
description | In a climate of economic uncertainty, cost effectiveness analysis is a potentially important tool for making choices about health care interventions. Methods for such analyses are well established, but the results need to be interpreted carefully and are subject to bias. Making decisions based on results of cost-effectiveness analyses can involve setting thresholds, but for individual patients, there needs to be disaggregation of benefits and harms included in a quality adjusted life year to ensure appropriate consideration of benefits and harms as well as personal preferences and circumstances. |
format | Online Article Text |
id | pubmed-3395827 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33958272012-07-14 Cost-effectiveness analysis for clinicians Hill, Suzanne R BMC Med Commentary In a climate of economic uncertainty, cost effectiveness analysis is a potentially important tool for making choices about health care interventions. Methods for such analyses are well established, but the results need to be interpreted carefully and are subject to bias. Making decisions based on results of cost-effectiveness analyses can involve setting thresholds, but for individual patients, there needs to be disaggregation of benefits and harms included in a quality adjusted life year to ensure appropriate consideration of benefits and harms as well as personal preferences and circumstances. BioMed Central 2012-02-01 /pmc/articles/PMC3395827/ /pubmed/22296610 http://dx.doi.org/10.1186/1741-7015-10-10 Text en Copyright ©2012 Hill; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Hill, Suzanne R Cost-effectiveness analysis for clinicians |
title | Cost-effectiveness analysis for clinicians |
title_full | Cost-effectiveness analysis for clinicians |
title_fullStr | Cost-effectiveness analysis for clinicians |
title_full_unstemmed | Cost-effectiveness analysis for clinicians |
title_short | Cost-effectiveness analysis for clinicians |
title_sort | cost-effectiveness analysis for clinicians |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395827/ https://www.ncbi.nlm.nih.gov/pubmed/22296610 http://dx.doi.org/10.1186/1741-7015-10-10 |
work_keys_str_mv | AT hillsuzanner costeffectivenessanalysisforclinicians |